Want to see PFE full AI Analyst Report?
Revenue by Segment
Provides insight into how different business units contribute to Pfizer's overall sales, highlighting areas of strength and potential growth or decline within the company's diverse operations.Global Biopharmaceuticals has shifted from COVID-era highs to a lower, seasonally pulsed baseline—quarterly swings reflect Comirnaty timing and muted Paxlovid demand—but underlying non‑COVID momentum from launches and acquisitions is helping plug the gap. Centreone is a steady, defensive manufacturing ramp that smooths revenue volatility, while Ignite is immaterial. Management’s cost-savings, legal settlements and BD proceeds materially reduce LOE risk and underpin the reaffirmed guidance and margin targets.
Date | Global Biopharmaceuticals | Centreone | Ignite |
|---|---|---|---|
Jun 30, 2026 | $14.66B | $373.00M | $0.00 |
Mar 31, 2026 | $14.16B | $289.00M | $0.00 |
Dec 31, 2025 | $17.14B | $409.00M | $4.00M |
Sep 30, 2025 | $16.31B | $344.00M | $0.00 |
Jun 30, 2025 | $14.30B | $328.00M | $20.00M |
Mar 31, 2025 | $13.44B | $257.00M | $17.00M |
Dec 31, 2024 | $17.41B | $325.00M | $26.00M |
Sep 30, 2024 | $17.39B | $285.00M | $25.00M |
Jun 30, 2024 | $12.99B | $278.00M | $15.00M |
Mar 31, 2024 | $14.60B | $258.00M | $17.00M |